FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
Jason E. Faris(Royal Marsden NHS Foundation Trust), Theodore S. Hong(Massachusetts General Hospital), Alexander R. Guimarães(Harvard University Press), Keith D. Lillemoe(Harvard University), Sarah P. Thayer(University of Nebraska Medical Center), Jackie Szymonifka(Cornell University), Cristina R. Ferrone(Cedars-Sinai Medical Center), Dushyant V. Sahani(Brigham and Women's Hospital), Janet E. Murphy(Harvard University), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Mai Anh Huynh(Dana-Farber Brigham Cancer Center), Eunice L. Kwak(Harvard University), Carlos Fernández-del Castillo(Massachusetts General Hospital), Jill N. Allen(Harvard University), Shaunagh McDermott(Massachusetts General Hospital), Lauren E. Dias(North Shore Community College), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center)
Cited by 280
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k